NCT06416566

Low-Dose Enoxaparin in Psoriasis

The Efficacy of Low-Dose Enoxaparin in Psoriasis

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Zagazig University · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Rationale: * Psoriasis is a chronic immune-mediated inflammatory skin disorder where T cells play a fundamental role in its pathogenesis. * Low molecular weight heparin has been reported to exert immunomodulatory effect at small doses through inhibition of T cells heparinase enzyme. * Low molecular weight heparin may have promising results for treatment of psoriasis. Research question: * Can low molecular weight heparin be used safely for treatment of psoriasis with good outcome? * Is enoxaparin inhibitory effect on T cell heparinase enzyme responsible for its beneficial effect? Hypothesis: * Low molecular weight heparin can achieve good results when used at small doses for treatment of psoriasis. * Heparin can exert immunomodulatory effect in psoriasis through inhibition of T cell heparinase enzyme. AIM OF WORK -The aim of this work is to assess the possible clinical efficacy and safety of low-dose enoxaparin in the treatment of psoriasis and to detect if inhibition of heparinase enzyme might account for its beneficial therapeutic effect. Objectives: * To evaluate safety and efficacy of low molecular weight heparin at small dose for treatment of psoriasis. * Contribute to the ongoing efforts to optimize psoriasis management and improve the lives of individuals affected by this chronic condition.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Subcutaneous Enoxaparin	Selected patients will receive subcutaneous low dose enoxaparin once a week for 6 weeks.The level of serum heparinase enzyme will be measured before and after treatment

Timeline

• Start date: 2024-05-15
• Primary completion: 2024-09-01
• Completion: 2024-10-01
• First posted: 2024-05-16
• Last updated: 2024-05-16